MiRus develops innovative cardiac medical devices for heart-valve treatment and repair.
$1.5BStrategic
Boston Scientific dropping $1.5B on a cardiac device company signals they're betting structural heart repair (especially valve work) is moving from niche to volume—likely because minimally invasive techniques are finally hitting adoption curves that justify acquisition-scale bets. If you're in adjacent med-tech (neurotech, orthopedic devices, anything procedural), watch how MiRus uses this capital: it'll probably go to clinical validation and manufacturing scale, not R&D, which means the category is past proof-of-concept and into 'can we make this routine.'